Basiliximab is a chimeric mouse-human monoclonal antibody used to prevent rejection in organ transplantation, especially in kidney transplants.
It competes with IL-2 to bind to the CD25 alpha chain subunit of the IL2 receptor on the surface of the activated T lymphocytes, prevents T cells from replicating and also from activating B cells, which are responsible for the production of antibodies, which would bind to the transplanted organ and stimulate an immune response against the transplant.
It is administered through intravenous injection 4 days after transplant.
In 2016, it sold €195 million in Europe.
Labs that test for drug level: